243 related articles for article (PubMed ID: 33090016)
1. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study.
Ozer K; Cooper AM; Ahn LP; Waggonner CR; Blevins TC
Diabetes Technol Ther; 2021 Apr; 23(4):286-292. PubMed ID: 33090016
[TBL] [Abstract][Full Text] [Related]
2. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
3. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
4. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
5. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
6. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
7. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Basu A; Pieber TR; Hansen AK; Sach-Friedl S; Erichsen L; Basu R; Haahr H
Diabetes Obes Metab; 2018 Jul; 20(7):1615-1622. PubMed ID: 29493118
[TBL] [Abstract][Full Text] [Related]
8. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
9. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study.
Ware J; Allen JM; Boughton CK; Cezar A; Hartnell S; Wilinska ME; Thankamony A; Deakin M; Leyland H; Phelan K; Thornborough K; Hovorka R
Diabetes Technol Ther; 2023 Jun; 25(6):431-436. PubMed ID: 36880866
[TBL] [Abstract][Full Text] [Related]
12. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
13. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
[TBL] [Abstract][Full Text] [Related]
14. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.
Komatsu M; Ekelund M; Horio H; Kadowaki T
Endocr J; 2021 Apr; 68(4):429-440. PubMed ID: 33390422
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
[TBL] [Abstract][Full Text] [Related]
19. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
